Ardea Biosciences Inc

Ardea Biosciences — Technical Presentation (September 2011)

6 slides from Ardea Biosciences's technical presentation, Sep 7, 2011

  1. Slide 1: Long-term Allopurinol Safety Trial (LASSO) and Phase 3 studies

    Exhibit 99.2 Long-term Allopurinol Safety Trial ( LASSO ) open-label interventional studies of allopurinol in gout patients otherwise eligible for the following Phase 3 studies: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders ( CLEAR #1 ) randomized, placebo-cont

  2. Slide 2: Evaluating in Gout Patients (LASSO - N. America & Global)

    Evaluating in Gout Patients ( LASSO - N. America & Global) L ong - term A llopurinol S afety S tudy O utcomes Population: Up to pts with hyperuricemia (sUA > mg/dL) at ~300 centers Design: Provide therapy with allopurinol at the medically appropriate doses; monitor patients for a minimum of 2 months

  3. Slide 3: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR - N. America)

    Study of in Standard of Care Inadequate ( CLEAR - N. America) C ombination LE sinurad A llopurinol R esponders Primary: proportion of subjects with sUA level < 6.0 mg/dL after 6 months Key Secondary: A ssessment of gout flare rate, tophi resolution and quality of li fe measurements. Screening Period

  4. Slide 4: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR - Global)

    Care Inadequate ( CLEAR - Global) C ombination Study of LE sinurad in A llopurinol Standard of R esponders Primary: proportion of subjects with sUA level < 6.0 mg/dL after months Key Secondary: Assessment of gout flare rate, tophi resolution and quality of life measurements. Screening Period 200 mg

  5. Slide 5: Lesinurad Monotherapy in Subjects Intolerant to Xanthine Oxidase Inhibitors (LIGHT - Global)

    Monotherapy in Subjects Intolerant to Xanthine Oxidase In h ibi t ors ( LIGHT - Global) L es I nurad G out Primary: Proportion of patients whose sUA levels are < 6.0 mg/dL after 6 months Screening Period 400 mg Placebo Placebo Patients Switched to Active at 6 months 400 mg

  6. Slide 6: Combination Treatment Study in Subjects with Tophaceous Gout Using Lesinurad and Febuxostat (CRYSTAL - Global)

    T R eatment Stud Y in with Gout Using and Febuxostat ( CRYSTAL - Global) C ombination S ubjects T oph A eous L esInurad Primary – proportion of subjects with sUA level < 5.0 mg/dL after 6 months Key Secondary - proportion of subjects with resolution of tophi at 6, 9 and 12 mos, gout flare rate and q

Ardea Biosciences — Technical Presentation (September 2011) on 6ix